PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

Discover the Global PharmaPoint: Prostate Cancer Market Drug Forecast
and Analysis to 2023
"The Report PharmaPoint: Prostate Cancer ­ Global Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. ­ MarketResearchReports.biz"
Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It
accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden
on healthcare systems. While patients diagnosed with early­stage, localized prostate cancer
can be cured, patients who are diagnosed with or progress to castration­resistant prostate
cancer (CRPC) have no curative options. This report focuses on the current treatment
landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. Since
2010, five new drugs have been approved for the treatment of CRPC: Dendreons Provenge,
Sanofis Jevtana, Johnson & Johnsons Zytiga, Medivation/Astellas Xtandi, and Bayers
Xofigo. During the forecast period from 2013­2023, GlobalData expects that nine new latestage
pipeline agents will launch, eight of which will be for the treatment of CRPC. As a
result of this unprecedented level of clinical development, GlobalData predicts there will be
massive changes in the CRPC treatment paradigm. In addition, due to the influx of new
therapies, the size of the prostate cancer market across the nine major pharmaceutical
markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will
increase three­fold.
View Report At :http://www.marketresearchreports.biz/analysis/295880
Highlights
Key Questions Answered
­ How will prostate cancer disease management change as new agents enter the market?
­ Which prostate cancer patients have the greatest unmet needs and how well will these
needs be addressed by the new agents?
­ What are the most dominant players in the prostate cancer space and what corporate
strategies are pursued by these companies?
­ What are the most promising late­stage pipeline agents for prostate cancer? How do they
compare to currently marketed products?
­ What opportunities will remain for future players following the launch of these pipeline
agents?
Key Findings

­ The prostate cancer market, in the 9MM is forecasted to rapidly increase from $2.6bn in
2013 to $8.3bn in 2023, at a CAGR of 12.4%. This growth will be driven by the label
extensions of currently marketed drugs as well as the launch of nine new premium­priced
therapies for the treatment of prostate cancer.
­ GlobalData expects Medivation and Astellas Xtandi will become the market leader in
prostate cancer. Xtandi is currently approved for pre­ and post­chemotherapy metastatic
castration­resistant prostate cancer (CRPC). Over the course of the forecast period,
GlobalData anticipates it will receive label extensions in non­metastatic CRPC and
hormone­sensitive prostate cancer, making it available to virtually all prostate cancer
patients segments, with the exception of those with localized disease.
­ The prostate cancer pipeline is robust with nine drugs in late­stage development. While
androgen biosynthesis is still a major target, many of the pipeline candidates have diverse
mechanisms of action and target proteins and pathways that are not targeted by the
currently marketed prostate cancer treatments. Among these new candidates are a
checkpoint inhibitor, a clusterin inhibitor, and an anti­angiogenic agent. There are also
several vaccines, both autologous and off­the­shelf, that have a significant presence in this
pipeline.
Download Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/295880
Scope
­ Overview of prostate cancer, including epidemiology, etiology, pathophysiology, clinical
staging, symptoms, prognosis, quality of life, and disease management.
­ Annualized prostate cancer therapeutics market revenue from 2013­2023. Annual cost of
therapy, and major marketed and pipeline drug sales in this forecast period are included.
­ Key topics covered include strategic competitor assessment, market characterization,
unmet needs, and implications for the prostate cancer therapeutics market.
­ Pipeline analysis: The prostate cancer pipeline is robust with many late­stage candidates
set to launch in the forecast period. Comprehensive analysis of the nine most promising
candidates in Phase III development are highlighted and profiled.
­ Analysis of the current and future market competition in the global prostate cancer
therapeutics market, including insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide qualitative analysis of its
implications.
Reasons to buy
­ Develop and design your in­licensing and out­licensing strategies through a review of
pipeline products and technologies, and by identifying the companies with the most robust
pipeline.
­ Develop business strategies by understanding the trends shaping and driving the 9MM
prostate cancer market.
­ Drive revenues by understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the 9MM prostate cancer therapeutics
market in the future.
­ Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analysing the performance of various competitors.

­ Identify emerging players with potentially strong product portfolios and create effective
counter­strategies to gain a competitive advantage.
­ Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and strategic
partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 24
3.2 Staging 25
3.3 Symptoms 29
3.4 Prognosis 29
3.5 Quality of Life 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 31
4.3 Global Trends 34
4.3.1 US 35
4.3.2 5EU 36
4.3.3 Japan, Brazil, and Canada 36
4.4 Forecast Methodology 37
4.4.1 Sources Used 38
4.4.2 Sources Not Used 44
4.4.3 Forecast Assumptions and Methods 45
4.5 Epidemiological Forecast for Prostate Cancer (2013­2023) 48
4.5.1 Diagnosed Incident Cases of Prostate Cancer 48
4.5.2 Age­Specific Diagnosed Incident Cases of Prostate Cancer 50
4.5.3 Age­Standardized Diagnosed Incidence of Prostate Cancer 52
4.5.4 Clinical Stage at Diagnosis 54
4.5.5 Diagnosed Five­Year Prevalent Cases of Prostate Cancer 55
4.5.6 Diagnosed Five­Year Prevalent Cases of CRPC 56
4.5.7 Diagnosed Five­Year Prevalent Cases of Bone Metastases Among CRPC Patients 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 61
4.6.3 Strengths of the Analysis 62
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreportsbiz

About us
MarketResearchReports.biz is the most comprehensive collection of market research
reports. MarketResearchReports.Biz services are specially designed to save time and money
for our clients. We are a one stop solution for all your research needs, our main offerings
are syndicated research reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1­518­621­2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz